Crossmark

Annual Injection of Zoledronic Acid Improves Bone Status in Children with Cerebral Palsy and Rett Syndrome

Crossref DOI link: https://doi.org/10.1007/s00223-018-0505-2

Published Online: 2018-12-15

Published Print: 2019-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wiedemann, Arnaud

Renard, Emeline

Hernandez, Magali

Dousset, Brigitte

Brezin, François

Lambert, Laetitia

Weryha, Georges

Feillet, François
License Information

Text and Data Mining valid from 2018-12-15
More Information

Article History

Received: 11 August 2018

Accepted: 7 December 2018

First Online: 15 December 2018

Compliance with Ethical Standards

:

: Arnaud Wiedemann, Emeline Renard, Magali Hernandez, Brigitte Dousset, François Brezin, Laetitia Lambert, Georges Weryha, and François Feillet declare that they have no conflict of interest.

: A written information with adverse events related to ZA utilization was given to every parents or legal guardians. Clinical trial has been approved by the Ethical Review Committee of the University Hospital of Nancy and is registered with the CNIL (French Institutional Ethics Committee of Protection and Liberties registration number: R2017-03). All clinical investigations were conducted in accordance to the Declaration of Helsinki.